ARVINAS INC. - COMMON STOCK

Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer

31 Jul 2023 16:30:14 By Nasdaq GlobeNewswire

Arvinas Announces Changes to its Board of Directors

15 Jun 2023 16:30:26 By Nasdaq GlobeNewswire

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations

08 Jun 2023 07:00:41 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

05 Jun 2023 07:00:49 By Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

08 May 2023 07:00:36 By Nasdaq GlobeNewswire

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update

05 May 2023 07:00:06 By Nasdaq GlobeNewswire

Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference

03 May 2023 07:00:01 By Nasdaq GlobeNewswire

Arvinas to Present at Stifel Targeted Oncology Day

21 Apr 2023 16:00:00 By Nasdaq GlobeNewswire

Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership

03 Apr 2023 07:00:16 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

27 Feb 2023 16:00:38 By Nasdaq GlobeNewswire

Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

23 Feb 2023 07:00:05 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

06 Feb 2023 16:30:14 By Nasdaq GlobeNewswire

Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:00:38 By Nasdaq GlobeNewswire

Arvinas Announces Changes to its Board of Directors

16 Dec 2022 09:00:37 By Nasdaq GlobeNewswire

Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)

22 Nov 2022 07:12:46 By Nasdaq GlobeNewswire

Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update

08 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Arvinas to Present at Upcoming Conferences

01 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award

27 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

03 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Arvinas Gives Back to Local Greater New Haven Community

30 Sep 2022 09:00:00 By Nasdaq GlobeNewswire